UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 19, 2010
ALKERMES, INC.
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
|
| PENNSYLVANIA
|
|
1-14131
|
|
23-2472830 |
| (State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.) |
| |
|
|
|
852 Winter Street
Waltham, Massachusetts
|
|
02451-1420 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code:
(781) 609-6000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
| Item 7.01. |
|
Regulation FD Disclosure |
On April 19, 2010, Eli Lilly and Co. (“Lilly”) and Amylin Pharmaceuticals, Inc (“Amylin”) announced
that Lilly submitted the Marketing Authorization Application filing for BYDUREON™ (exenatide for
extended-release injectable suspension) for the treatment of type 2 diabetes to the European
Medicines Agency. Alkermes, Inc. (“Alkermes”), Amylin, and Lilly are working together to develop
BYDUREON, a subcutaneous injection of exenatide for the treatment of type 2 diabetes that utilizes
Alkermes’ proprietary Medisorb® technology to create an extended-release injection.
BYDUREON is not currently approved by any regulatory agencies. This information shall not be deemed
“filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing
under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.